HMR-3562. Aventis Pharma.

Z, Ma; A S, Florjancic

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2002

Data sources: Europe PubMed Central

HMR-3562. Aventis Pharma.

descriptionPublicationkeyboard_double_arrow_right Article 29 Aug 2002 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 2 (issn: 1472-4472,

Copyright policy )

Authors: Z, Ma; A S, Florjancic;

pmid: 11892931

HMR-3562. Aventis Pharma.

- Summary
- Subjects
- Metrics

Abstract

Aventis Pharma (formerly Hoechst Marion Roussel) is investigating the ketolides HMR-3562 and HMR-3787 as potential antibacterial agents. The compounds belong to a series of 2-fluoroketolides. They have exhibited potency against a range of gram-positive bacteria and other respiratory tract pathogens including Haemophilus influenzae in vitro and in vivo.

Related Organizations

Abbott (United States)
United States
Seattle Institute for Biomedical and Clinical Research
United States

Keywords

Structure-Activity Relationship, Bacteria, Animals, Humans, Bacterial Infections, Macrolides, Anti-Bacterial Agents

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average